当前位置: 首页 >> 检索结果
221. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
作者: Alice B Gottlieb.;Vibeke Strand.;Mitsumasa Kishimoto.;Philip Mease.;Diamant Thaçi.;Julie Birt.;Chin H Lee.;Catherine L Shuler.;Chen-Yen Lin.;Dafna D Gladman.
来源: Rheumatology (Oxford). 2018年57卷10期1777-1788页
To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52 weeks.
222. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
作者: Masanari Shiramoto.;Sha Liu.;Zancong Shen.;Xiaohong Yan.;Amy Yamamoto.;Michael Gillen.;Yasushi Ito.;Jesse Hall.
来源: Rheumatology (Oxford). 2018年57卷9期1602-1610页
Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia. The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-dose pharmacodynamics, pharmacokinetics and safety of oral verinurad combined with febuxostat vs febuxostat alone and verinurad alone.
223. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
作者: Mark C Genovese.;Janet van Adelsberg.;Chunpeng Fan.;Neil M H Graham.;Hubert van Hoogstraten.;Janie Parrino.;Erin K Mangan.;Alberto Spindler.;Tom W J Huizinga.;Désirée van der Heijde.; .
来源: Rheumatology (Oxford). 2018年57卷8期1423-1431页
To examine 2-year safety, efficacy and radiographic outcomes of sarilumab in adults with RA and inadequate response to MTX (MTX-IR).
224. Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial.
作者: Tommaso Schioppo.;Annalisa Orenti.;Patrizia Boracchi.;Orazio De Lucia.;Antonella Murgo.;Francesca Ingegnoli.
来源: Rheumatology (Oxford). 2018年57卷8期1408-1416页
I.v. iloprost (ILO) may be used in the treatment of refractory RP and digital ulcers. We aim to evaluate the acute and chronic effects of two different ILO regimens by power Doppler US (PDUS) and nailfold videocapillaroscopy.
225. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.
作者: Walter P Maksymowych.;Désirée van der Heijde.;Xenofon Baraliakos.;Atul Deodhar.;Sarah P Sherlock.;David Li.;Dona Fleishaker.;Thijs Hendrikx.;Keith S Kanik.
来源: Rheumatology (Oxford). 2018年57卷8期1390-1399页
Minimally important changes (MICs) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI scores are ⩾2.5 for SI joint and ⩾5 for spine. This post hoc analysis assessed achievement of MIC in SPARCC scores in biologic-naïve patients with AS treated with tofacitinib or placebo, and correlation with clinical responses.
226. The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial.
作者: Daniel H Solomon.;Peter Libby.;Neville D Yeomans.;Qiuqing Wang.;Kathy E Wolski.;Steven E Nissen.;M Elaine Husni.
来源: Rheumatology (Oxford). 2018年57卷8期1364-1369页
Guidelines exist for the use of low-dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit considerations may differ in RA. While RA confers an increased CV risk, such patients more likely use NSAIDs and corticosteroids.
227. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.
作者: Ippei Miyagawa.;Shingo Nakayamada.;Kazuhisa Nakano.;Satoshi Kubo.;Shigeru Iwata.;Yusuke Miyazaki.;Maiko Yoshikawa.;Hiroko Yoshinari.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2019年58卷2期336-344页
We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA.
228. Cost-effectiveness of a model consultation to support self-management in patients with osteoarthritis.
作者: Raymond Oppong.;Sue Jowett.;Martyn Lewis.;Kris Clarkson.;Zoe Paskins.;Peter Croft.;John J Edwards.;Emma Healey.;Kelvin P Jordan.;Andrew Morden.;Bie Nio Ong.;Mark Porcheret.;Andrew Finney.;Elaine Hay.;Krysia Dziedzic.
来源: Rheumatology (Oxford). 2018年57卷6期1056-1063页
The aim of this study was to estimate the cost-effectiveness of a model OA consultation for OA to support self-management compared with usual care.
229. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.
作者: Stephan Reichenbach.;Sabine Adler.;Harald Bonel.;Jennifer L Cullmann.;Stefan Kuchen.;Lukas Bütikofer.;Michael Seitz.;Peter M Villiger.
来源: Rheumatology (Oxford). 2018年57卷6期982-986页
To analyse magnetic resonance angiographic (MRA) vessel wall signals from a randomized controlled trial of tocilizumab (TCZ) to treat GCA.
230. Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients.
作者: Monika M Schoels.;Uriel Landesmann.;Farideh Alasti.;Daniel Baker.;Josef S Smolen.;Daniel Aletaha.
来源: Rheumatology (Oxford). 2018年57卷6期969-976页
In PsA management, remission and low disease activity represent preferential treatment targets. We aimed at evaluating the predictive value and clinical use of initial therapeutic response for subsequent achievement of these targets.
231. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
作者: Mark C Genovese.;Joel M Kremer.;Cynthia E Kartman.;Douglas E Schlichting.;Li Xie.;Tara Carmack.;Carlos Pantojas.;Juan Sanchez Burson.;Hans-Peter Tony.;William L Macias.;Terence P Rooney.;Josef S Smolen.
来源: Rheumatology (Oxford). 2018年57卷5期900-908页
RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety.
232. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
作者: Divi Cornec.;Brian F Kabat.;John R Mills.;Melissa Cheu.;Amber M Hummel.;Darrell R Schroeder.;Matthew D Cascino.;Paul Brunetta.;David L Murray.;Melissa R Snyder.;Fernando Fervenza.;Gary S Hoffman.;Cees G M Kallenberg.;Carol A Langford.;Peter A Merkel.;Paul A Monach.;Philip Seo.;Robert F Spiera.;E William St Clair.;John H Stone.;David R Barnidge.;Ulrich Specks.
来源: Rheumatology (Oxford). 2018年57卷4期639-650页
To study the determinants of the pharmacokinetics (PK) of rituximab (RTX) in patients with ANCA-associated vasculitis (AAV) and its association with clinical outcomes.
233. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
作者: Christopher J Edwards.;Andrew J K Östör.;Barbara Naisbett-Groet.;Patrick Kiely.
来源: Rheumatology (Oxford). 2018年57卷1期84-91页
To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX.
234. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
作者: Xavier M Teitsma.;Johannes W G Jacobs.;Paco M J Welsing.;Attila Pethö-Schramm.;Michelle E A Borm.;Jacob M van Laar.;Floris P J G Lafeber.;Johannes W J Bijlsma.
来源: Rheumatology (Oxford). 2018年57卷2期309-317页
To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands in the U-Act-Early trial.
235. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
作者: Michael B Arnold.;Dinesh Khanna.;Christopher P Denton.;Jacob M van Laar.;Tracy M Frech.;Marina E Anderson.;Murray Baron.;Lorinda Chung.;Gerhard Fierlbeck.;Santhanam Lakshminarayanan.;Yannick Allanore.;Gabriela Riemekasten.;Virginia Steen.;Ulf Müller-Ladner.;Helen Spotswood.;Laura Burke.;Jeffrey Siegel.;Angelika Jahreis.;Daniel E Furst.;Janet E Pope.
来源: Rheumatology (Oxford). 2018年57卷1期152-157页
Patient acceptable symptom state (PASS) as an absolute state of well-being has shown promise as an outcome measure in many rheumatologic conditions. We aimed to assess whether PASS may be effective in active diffuse cutaneous SSc differentiating active from placebo.
236. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
作者: Xiang Guo.;Brandon W Higgs.;Anne-Christine Bay-Jensen.;Yuling Wu.;Morten A Karsdal.;Michael Kuziora.;Alex Godwood.;David Close.;Patricia C Ryan.;Lorin K Roskos.;Wendy I White.
来源: Rheumatology (Oxford). 2018年57卷1期175-184页
Targeting the granulocyte-macrophage colony-stimulating factor (GM-CSF) pathway holds great potential in the treatment of inflammatory diseases. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody, has demonstrated clinical efficacy in RA. Our current study aimed to elucidate mechanisms of action and identify peripheral biomarkers associated with therapeutic responses of GM-CSF antagonism in RA.
237. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
作者: Anne-Kathrin Tausche.;Rieke Alten.;Nicola Dalbeth.;Jeff Kopicko.;Maple Fung.;Scott Adler.;Nihar Bhakta.;Chris Storgard.;Scott Baumgartner.;Kenneth Saag.
来源: Rheumatology (Oxford). 2017年56卷12期2170-2178页
To investigate the efficacy and safety of lesinurad, a selective uric acid reabsorption inhibitor, in a 6 month, phase 3 clinical trial and extension study.
238. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
作者: Xavier M Teitsma.;Johannes W G Jacobs.;Paco M J Welsing.;Attila Pethö-Schramm.;Michelle E A Borm.;Lidy Hendriks.;Natasja H A M Denissen.;Jacob M van Laar.;Floris P J G Lafeber.;Johannes W J Bijlsma.
来源: Rheumatology (Oxford). 2017年56卷12期2179-2189页
To evaluate the effect of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early RA.
239. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
作者: Fowzia Ibrahim.;Beatriz Lorente-Cánovas.;Caroline J Doré.;Ailsa Bosworth.;Margaret H Ma.;James B Galloway.;Andrew P Cope.;Ira Pande.;David Walker.;David L Scott.
来源: Rheumatology (Oxford). 2017年56卷11期2004-2014页
RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response.
240. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
作者: Paul Emery.;Jirí Vencovský.;Anna Sylwestrzak.;Piotr Leszczynski.;Wieslawa Porawska.;Asta Baranauskaite.;Vira Tseluyko.;Vyacheslav M Zhdan.;Barbara Stasiuk.;Roma Milasiene.;Aaron Alejandro Barrera Rodriguez.;Soo Yeon Cheong.;Jeehoon Ghil.
来源: Rheumatology (Oxford). 2017年56卷12期2093-2101页
To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA.
|